DNTH Stock News & Analysis | Latest Updates

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the 44th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 p.m. EST and will host one-on-one meetings with investors.

January 5, 2026

DNTH News

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views

Baird Maintains Outperform on Dianthus Therapeutics, Lowers Price Target to $50

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

Dianthus Therapeutics Q1 EPS $(0.82) Beats $(0.85) Estimate, Sales $1.16M Beat $804.30K Estimate

Dianthus Therapeutics Q1 EPS $(0.82) Beats $(0.85) Estimate

Dianthus Completes Enrollment In Phase 2 MaGic Trial Of DNTH103 For gMG, Top-Line Results Expected September

Dianthus Therapeutics Completes Enrollment In Phase 2 MaGic Trial Of DNTH103; Top-Line Results Expected in September

Wedbush Reiterates Outperform on Dianthus Therapeutics, Maintains $36 Price Target

Guggenheim Reiterates Buy on Dianthus Therapeutics, Maintains $84 Price Target

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

Dianthus Therapeutics Q4 EPS $(0.81) Beats $(0.85) Estimate, Sales $1.32M Beat $859.70K Estimate

Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics

TD Cowen Initiates Coverage On Dianthus Therapeutics with Buy Rating

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

HC Wainwright & Co. Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $40